Payment overview · 2025
General Payments
$3,538.14
86 reported records · 15 companies
Healthcare provider profile · identity verified
Bharat K Mehta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EASTON, PA · NPI 1033104484
Verified facts
What the public records show
CMS Open Payments records show Bharat K Mehta, MD received $3,538.14 in general payments during 2025 across 86 reported records.
Lilly USA, LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Jardiance, Kerendia, Lokelma, Mounjaro, Nuplazid, Nurtec Odt, Otezla, Ozempic, Rexulti.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuplazid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 552 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 552 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 965 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $603.12 | 17.1% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $597.74 | 16.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $479.64 | 13.6% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $401.09 | 11.3% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $306.31 | 8.7% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $250.78 | 7.1% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $196.46 | 5.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $165.09 | 4.7% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$162.64 | 4.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.43 | 4.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $65.80 | 1.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.48 | 1.7% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $52.92 | 1.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.07 | 0.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.57 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,446.89 | 85 |
| Education | $91.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $461.96 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $321.69 | 12 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $309.84 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $306.31 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $296.56 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $250.78 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $249.48 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $212.88 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.46 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $166.29 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $165.09 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.43 | 3 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $124.00 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $102.40 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $65.80 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $61.48 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.31 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $52.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.82 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.43 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 246 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 552 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 113 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
246 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
113 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
552 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
552 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
247 | 30 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
965 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3400 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 2394 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2257 | 83 |
| Quetiapine Fumarate | Quetiapine Fumarate | 2181 | 68 |
| Gabapentin | Gabapentin | 1532 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1498 | 66 |
| Sertraline Hcl | Sertraline Hcl | 1486 | 49 |
| Mirtazapine | Mirtazapine | 1408 | 52 |
| Losartan Potassium | Losartan Potassium | 1375 | 63 |
| Lisinopril | Lisinopril | 1207 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1071 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 1036 | 57 |
| Potassium Chloride | Potassium Chloride | 976 | 53 |
| Eliquis | Apixaban | 965 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 929 | 49 |
| Buspirone Hcl | Buspirone Hcl | 923 | 34 |
| Trazodone Hcl | Trazodone Hcl | 912 | 33 |
| Divalproex Sodium | Divalproex Sodium | 853 | 41 |
| Furosemide | Furosemide | 725 | 48 |
| Olanzapine | Olanzapine | 723 | 34 |
| Metformin Hcl | Metformin Hcl | 644 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 640 | 19 |
| Risperidone | Risperidone | 627 | 21 |
| Memantine Hcl | Memantine Hcl | 584 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 578 | 41 |
| Allopurinol | Allopurinol | 571 | 26 |
| Famotidine | Famotidine | 561 | 25 |
| Jardiance | Empagliflozin | 552 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 509 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 497 | 21 |
| Carvedilol | Carvedilol | 486 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 480 | 28 |
| Donepezil Hcl | Donepezil Hcl | 463 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 394 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 373 | 49 |
| Finasteride | Finasteride | 371 | 13 |
| Omeprazole | Omeprazole | 292 | 30 |
| Xarelto | Rivaroxaban | 271 | 17 |
| Simvastatin | Simvastatin | 258 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 257 | suppressed |
| Vascepa | Icosapent Ethyl | 254 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 250 | suppressed |
| Trulicity | Dulaglutide | 247 | 30 |
| Farxiga | Dapagliflozin Propanediol | 246 | 11 |
| Baclofen | Baclofen | 245 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 244 | suppressed |
| Ezetimibe | Ezetimibe | 237 | 19 |
| Levetiracetam | Levetiracetam | 234 | 11 |
| Myrbetriq | Mirabegron | 232 | suppressed |
| Haloperidol | Haloperidol | 214 | suppressed |
| Aripiprazole | Aripiprazole | 213 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 213 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 213 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 208 | suppressed |
| Bumetanide | Bumetanide | 207 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 200 | 15 |
| Topiramate | Topiramate | 200 | suppressed |
| Lamotrigine | Lamotrigine | 195 | suppressed |
| Prednisone | Prednisone | 188 | 52 |
| Bupropion Xl | Bupropion Hcl | 184 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 182 | 29 |
| Tramadol Hcl | Tramadol Hcl | 182 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 181 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 168 | suppressed |
| Torsemide | Torsemide | 163 | 11 |
| Valsartan | Valsartan | 163 | 14 |
| Warfarin Sodium | Warfarin Sodium | 145 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 140 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 137 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 136 | suppressed |
| Januvia | Sitagliptin Phosphate | 131 | 11 |
| Lubiprostone | Lubiprostone | 130 | suppressed |
| Glipizide | Glipizide | 129 | suppressed |
| Linzess | Linaclotide | 129 | 28 |
| Xifaxan | Rifaximin | 124 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 123 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 121 | suppressed |
| Fenofibrate | Fenofibrate | 117 | suppressed |
| Lovastatin | Lovastatin | 117 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 114 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 114 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | suppressed |
| Latanoprost | Latanoprost | 114 | 20 |
| Lithium Carbonate | Lithium Carbonate | 114 | suppressed |
| Kerendia | Finerenone | 113 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 113 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 106 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | suppressed |
| Primidone | Primidone | 101 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 98 | suppressed |
| Alprazolam | Alprazolam | 97 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 96 | 15 |
| Azithromycin | Azithromycin | 92 | 73 |
| Methocarbamol | Methocarbamol | 90 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | suppressed |
| Atenolol | Atenolol | 87 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 11 |
| Clonazepam | Clonazepam | 82 | 16 |
| Spironolactone | Spironolactone | 82 | suppressed |
| Lactulose | Lactulose | 81 | suppressed |
| Lorazepam | Lorazepam | 78 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 78 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 77 | 19 |
| Gemtesa | Vibegron | 75 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 73 | 19 |
| Nifedipine Er | Nifedipine | 72 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 16 |
| Novolog Flexpen | Insulin Aspart | 68 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | suppressed |
| Austedo | Deutetrabenazine | 65 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 58 | suppressed |
| Amantadine | Amantadine Hcl | 57 | suppressed |
| Rexulti | Brexpiprazole | 56 | suppressed |
| Nyamyc | Nystatin | 54 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 35 |
| Nurtec Odt | Rimegepant Sulfate | 53 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 51 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 51 | suppressed |
| Methimazole | Methimazole | 51 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 45 | suppressed |
| Zonisamide | Zonisamide | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Nadolol | Nadolol | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 41 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 41 | suppressed |
| Ingrezza | Valbenazine Tosylate | 40 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 37 | 21 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Silodosin | Silodosin | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Metolazone | Metolazone | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 25 |
| Lidocaine Hcl | Lidocaine Hcl | 31 | 25 |
| Mirabegron Er | Mirabegron | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 24 |
| Haloperidol Lactate | Haloperidol Lactate | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | suppressed |
| Symproic | Naldemedine Tosylate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Glucagon Emergency Kit | Glucagon | 28 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | 11 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 17 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 14 |
| Nitroglycerin | Nitroglycerin | 23 | 20 |
| Fluconazole | Fluconazole | 22 | 13 |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Otezla | Apremilast | 20 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Valproic Acid | Valproic Acid | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 15 | suppressed |
| Risperidone Odt | Risperidone | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Linezolid-D5w | Linezolid In Dextrose 5% | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,538.14 · 86 records | Lilly USA, LLC | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, FARXIGA, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LOKELMA, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Tymlos, WAINUA, Wegovy, XCOPRI, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error